Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes
Patients with type 2 diabetes (T2D) have approximately twice the risk of developing cardiovascular (CV) disease (CVD) [1] and a 2.5-fold increased risk of heart failure (HF) [2] compared with individuals without diabetes. Every 1-mmol/L (18-mg/dL) increase in fasting glucose levels increases the risk of CV events or death by 17% [3]. Results from studies investigating the impact of intensive glucose lowering are contradictory. Early trials comparing intensive glucose control versus standard therapy failed to demonstrate reduced CV mortality [4 –7], and benefits for CV risk reduction have only emerged after long-term follow-up and meta-analysis [8–11].
Source: Primary Care Diabetes - Category: Primary Care Authors: Robert J. Chilton, Kathleen M. Dungan, Jay H. Shubrook, Guillermo E. Umpierrez Tags: Review Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Primary Care | Study